| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 64 | 2022 | 625 | 8.160 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 45 | 2021 | 316 | 5.690 |
Why?
|
| Pneumonectomy | 28 | 2022 | 67 | 3.540 |
Why?
|
| Lymph Nodes | 8 | 2015 | 70 | 2.140 |
Why?
|
| Sentinel Lymph Node Biopsy | 7 | 2015 | 14 | 1.770 |
Why?
|
| Neoplasm Staging | 33 | 2021 | 340 | 1.470 |
Why?
|
| Biomarkers, Tumor | 10 | 2022 | 175 | 1.170 |
Why?
|
| Radiopharmaceuticals | 5 | 2009 | 48 | 1.160 |
Why?
|
| Thoracic Surgery, Video-Assisted | 5 | 2015 | 17 | 1.100 |
Why?
|
| Adenocarcinoma | 8 | 2014 | 189 | 1.090 |
Why?
|
| Mesothelioma | 6 | 2012 | 10 | 1.090 |
Why?
|
| Esophageal Neoplasms | 4 | 2011 | 45 | 0.970 |
Why?
|
| Humans | 89 | 2022 | 29337 | 0.970 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2019 | 178 | 0.920 |
Why?
|
| Neoadjuvant Therapy | 8 | 2015 | 53 | 0.920 |
Why?
|
| Bronchoscopy | 6 | 2019 | 25 | 0.890 |
Why?
|
| Lymphatic Metastasis | 12 | 2015 | 81 | 0.880 |
Why?
|
| Postoperative Complications | 12 | 2022 | 957 | 0.870 |
Why?
|
| Pleural Neoplasms | 6 | 2012 | 9 | 0.840 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2017 | 184 | 0.780 |
Why?
|
| Aged | 47 | 2021 | 9448 | 0.750 |
Why?
|
| Respiration, Artificial | 1 | 2021 | 107 | 0.730 |
Why?
|
| Prognosis | 18 | 2022 | 840 | 0.710 |
Why?
|
| Male | 54 | 2021 | 15621 | 0.700 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2019 | 11 | 0.700 |
Why?
|
| False Positive Reactions | 1 | 2019 | 33 | 0.700 |
Why?
|
| Thoracic Surgery | 7 | 2022 | 28 | 0.700 |
Why?
|
| Female | 52 | 2021 | 16197 | 0.680 |
Why?
|
| Unnecessary Procedures | 1 | 2019 | 24 | 0.680 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 3 | 2009 | 7 | 0.600 |
Why?
|
| Middle Aged | 43 | 2021 | 9823 | 0.600 |
Why?
|
| Mediastinal Neoplasms | 2 | 2009 | 12 | 0.590 |
Why?
|
| Carcinoma, Bronchogenic | 1 | 2015 | 11 | 0.550 |
Why?
|
| Risk Assessment | 10 | 2021 | 679 | 0.520 |
Why?
|
| Anastomosis, Surgical | 2 | 2011 | 34 | 0.510 |
Why?
|
| Breast Neoplasms | 2 | 2007 | 329 | 0.470 |
Why?
|
| Aged, 80 and over | 22 | 2018 | 4851 | 0.460 |
Why?
|
| Treatment Outcome | 21 | 2017 | 3478 | 0.450 |
Why?
|
| Mediastinitis | 2 | 2009 | 6 | 0.440 |
Why?
|
| Solitary Pulmonary Nodule | 3 | 2015 | 11 | 0.430 |
Why?
|
| Survival Rate | 11 | 2021 | 349 | 0.430 |
Why?
|
| Pulmonary Diffusing Capacity | 3 | 2016 | 5 | 0.430 |
Why?
|
| Carbon Monoxide | 2 | 2022 | 5 | 0.420 |
Why?
|
| Mediastinal Diseases | 1 | 2012 | 4 | 0.420 |
Why?
|
| Histoplasmosis | 1 | 2012 | 8 | 0.420 |
Why?
|
| Esophagectomy | 1 | 2011 | 21 | 0.420 |
Why?
|
| Chemoradiotherapy | 6 | 2015 | 67 | 0.420 |
Why?
|
| Practice Management, Medical | 1 | 2011 | 3 | 0.410 |
Why?
|
| Adult | 26 | 2017 | 8601 | 0.410 |
Why?
|
| Colorectal Neoplasms | 2 | 2009 | 82 | 0.390 |
Why?
|
| Airway Obstruction | 2 | 2017 | 18 | 0.390 |
Why?
|
| Xanthine Dehydrogenase | 1 | 2010 | 6 | 0.380 |
Why?
|
| Survival Analysis | 11 | 2017 | 298 | 0.380 |
Why?
|
| Colon | 1 | 2011 | 148 | 0.380 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2015 | 290 | 0.380 |
Why?
|
| Predictive Value of Tests | 7 | 2014 | 521 | 0.370 |
Why?
|
| Aspergillus flavus | 1 | 2009 | 3 | 0.360 |
Why?
|
| Mediastinum | 1 | 2009 | 6 | 0.360 |
Why?
|
| Early Detection of Cancer | 5 | 2022 | 79 | 0.360 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2010 | 100 | 0.360 |
Why?
|
| Aspergillosis | 1 | 2009 | 10 | 0.360 |
Why?
|
| Retrospective Studies | 17 | 2022 | 3273 | 0.360 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2009 | 8 | 0.350 |
Why?
|
| Tomography, X-Ray Computed | 9 | 2015 | 770 | 0.350 |
Why?
|
| Carcinoid Tumor | 1 | 2008 | 8 | 0.340 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2008 | 7 | 0.340 |
Why?
|
| Diagnosis, Differential | 8 | 2018 | 389 | 0.340 |
Why?
|
| Monitoring, Intraoperative | 1 | 2009 | 37 | 0.340 |
Why?
|
| Neoplasms, Second Primary | 1 | 2008 | 30 | 0.330 |
Why?
|
| Catheterization | 2 | 2007 | 51 | 0.320 |
Why?
|
| Device Removal | 2 | 2008 | 85 | 0.320 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2009 | 31 | 0.320 |
Why?
|
| Diagnostic Imaging | 1 | 2009 | 90 | 0.320 |
Why?
|
| Preoperative Care | 4 | 2015 | 135 | 0.320 |
Why?
|
| Cohort Studies | 10 | 2018 | 1939 | 0.320 |
Why?
|
| Pleural Effusion, Malignant | 1 | 2007 | 3 | 0.320 |
Why?
|
| Genital Neoplasms, Female | 1 | 2007 | 10 | 0.320 |
Why?
|
| Positron-Emission Tomography | 1 | 2008 | 88 | 0.310 |
Why?
|
| Combined Modality Therapy | 8 | 2015 | 364 | 0.300 |
Why?
|
| Follow-Up Studies | 11 | 2021 | 1830 | 0.290 |
Why?
|
| Multivariate Analysis | 7 | 2017 | 324 | 0.280 |
Why?
|
| Insulin-Like Growth Factor I | 3 | 2022 | 54 | 0.280 |
Why?
|
| Multiple Pulmonary Nodules | 2 | 2018 | 9 | 0.270 |
Why?
|
| Immunoassay | 2 | 2018 | 41 | 0.270 |
Why?
|
| Lung | 3 | 2022 | 154 | 0.250 |
Why?
|
| Superior Vena Cava Syndrome | 1 | 2003 | 5 | 0.240 |
Why?
|
| Thoracoscopy | 5 | 2019 | 16 | 0.240 |
Why?
|
| Disease-Free Survival | 6 | 2017 | 175 | 0.240 |
Why?
|
| Cesarean Section | 1 | 2003 | 30 | 0.230 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2003 | 42 | 0.230 |
Why?
|
| Lymph Node Excision | 4 | 2015 | 26 | 0.230 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 2 | 2014 | 11 | 0.230 |
Why?
|
| Stents | 2 | 2017 | 76 | 0.230 |
Why?
|
| Thoracic Wall | 2 | 2016 | 8 | 0.230 |
Why?
|
| Databases, Factual | 7 | 2021 | 330 | 0.220 |
Why?
|
| Registries | 2 | 2021 | 188 | 0.210 |
Why?
|
| Weight Gain | 2 | 2012 | 66 | 0.200 |
Why?
|
| Radionuclide Imaging | 3 | 2009 | 56 | 0.200 |
Why?
|
| Biopsy | 4 | 2012 | 234 | 0.200 |
Why?
|
| Tidal Volume | 1 | 2021 | 11 | 0.200 |
Why?
|
| Pneumonia | 2 | 2019 | 67 | 0.190 |
Why?
|
| DNA Methylation | 2 | 2012 | 124 | 0.190 |
Why?
|
| Sensitivity and Specificity | 4 | 2018 | 553 | 0.190 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2012 | 162 | 0.190 |
Why?
|
| Autoantibodies | 2 | 2010 | 100 | 0.180 |
Why?
|
| Risk Factors | 8 | 2022 | 2443 | 0.180 |
Why?
|
| Patient Selection | 1 | 2021 | 232 | 0.180 |
Why?
|
| Esophagus | 2 | 2011 | 59 | 0.180 |
Why?
|
| Gases | 1 | 2019 | 6 | 0.180 |
Why?
|
| Algorithms | 6 | 2014 | 400 | 0.180 |
Why?
|
| Histiocytoma, Benign Fibrous | 1 | 1999 | 6 | 0.180 |
Why?
|
| Mediastinoscopy | 1 | 2019 | 3 | 0.180 |
Why?
|
| Osteosarcoma | 1 | 1999 | 29 | 0.180 |
Why?
|
| History, 20th Century | 2 | 2016 | 84 | 0.170 |
Why?
|
| Sarcoma | 2 | 2009 | 65 | 0.170 |
Why?
|
| United States | 5 | 2021 | 2333 | 0.170 |
Why?
|
| HLA Antigens | 1 | 2018 | 17 | 0.160 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2018 | 13 | 0.160 |
Why?
|
| Bone Neoplasms | 1 | 1999 | 101 | 0.160 |
Why?
|
| Syndecan-1 | 1 | 2018 | 8 | 0.160 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2018 | 19 | 0.160 |
Why?
|
| Neovascularization, Pathologic | 2 | 2015 | 56 | 0.160 |
Why?
|
| Nerve Growth Factors | 1 | 2018 | 44 | 0.160 |
Why?
|
| Tracheomalacia | 1 | 2017 | 2 | 0.160 |
Why?
|
| Tracheal Stenosis | 1 | 2017 | 4 | 0.160 |
Why?
|
| Silicones | 1 | 2017 | 8 | 0.160 |
Why?
|
| Area Under Curve | 3 | 2014 | 66 | 0.150 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2016 | 43 | 0.140 |
Why?
|
| Ribs | 1 | 2016 | 15 | 0.140 |
Why?
|
| Metformin | 1 | 2016 | 21 | 0.140 |
Why?
|
| Proportional Hazards Models | 3 | 2016 | 340 | 0.140 |
Why?
|
| Cardiology | 1 | 2016 | 73 | 0.140 |
Why?
|
| Heart Diseases | 1 | 2016 | 73 | 0.140 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2012 | 22 | 0.140 |
Why?
|
| Hypoglycemic Agents | 1 | 2016 | 56 | 0.140 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 142 | 0.130 |
Why?
|
| Disease Progression | 4 | 2014 | 787 | 0.130 |
Why?
|
| Adolescent | 5 | 2022 | 2279 | 0.130 |
Why?
|
| Carcinoma | 2 | 2015 | 57 | 0.130 |
Why?
|
| Lung Diseases, Fungal | 1 | 2015 | 9 | 0.130 |
Why?
|
| Mucormycosis | 1 | 2015 | 8 | 0.130 |
Why?
|
| Early Medical Intervention | 1 | 2015 | 14 | 0.130 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2014 | 8 | 0.130 |
Why?
|
| Clinical Trials as Topic | 2 | 2012 | 324 | 0.130 |
Why?
|
| Periodicals as Topic | 1 | 2015 | 41 | 0.130 |
Why?
|
| Feasibility Studies | 2 | 2009 | 227 | 0.130 |
Why?
|
| Biopsy, Needle | 2 | 2008 | 101 | 0.130 |
Why?
|
| Cytokines | 2 | 2014 | 347 | 0.120 |
Why?
|
| Radiotherapy, Conformal | 1 | 2014 | 19 | 0.120 |
Why?
|
| Thoracotomy | 5 | 2016 | 22 | 0.120 |
Why?
|
| Social Class | 1 | 2014 | 64 | 0.120 |
Why?
|
| Radiotherapy, Adjuvant | 5 | 2011 | 62 | 0.120 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2016 | 200 | 0.110 |
Why?
|
| Prosthesis Failure | 1 | 2017 | 556 | 0.110 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2013 | 7 | 0.110 |
Why?
|
| Genes, p16 | 1 | 2012 | 4 | 0.110 |
Why?
|
| Carcinoma, Small Cell | 2 | 2010 | 71 | 0.110 |
Why?
|
| Intraoperative Period | 2 | 2004 | 29 | 0.110 |
Why?
|
| Young Adult | 4 | 2014 | 1932 | 0.110 |
Why?
|
| Time Factors | 4 | 2019 | 1616 | 0.110 |
Why?
|
| Esophageal Stenosis | 1 | 2011 | 3 | 0.110 |
Why?
|
| Stomach | 1 | 2011 | 18 | 0.110 |
Why?
|
| Therapies, Investigational | 1 | 2011 | 7 | 0.100 |
Why?
|
| C-Peptide | 1 | 2011 | 7 | 0.100 |
Why?
|
| Forced Expiratory Volume | 2 | 2009 | 8 | 0.100 |
Why?
|
| Group Practice | 1 | 2011 | 1 | 0.100 |
Why?
|
| Appointments and Schedules | 1 | 2011 | 13 | 0.100 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2011 | 13 | 0.100 |
Why?
|
| Administrative Personnel | 1 | 2011 | 9 | 0.100 |
Why?
|
| Chemotherapy, Adjuvant | 4 | 2011 | 75 | 0.100 |
Why?
|
| Analysis of Variance | 4 | 2015 | 321 | 0.100 |
Why?
|
| Mentors | 1 | 2011 | 47 | 0.100 |
Why?
|
| Antineoplastic Agents | 4 | 2014 | 218 | 0.100 |
Why?
|
| Length of Stay | 6 | 2016 | 317 | 0.100 |
Why?
|
| Probability | 2 | 2008 | 94 | 0.100 |
Why?
|
| Chemoradiotherapy, Adjuvant | 3 | 2015 | 16 | 0.100 |
Why?
|
| Blood Chemical Analysis | 1 | 2010 | 13 | 0.100 |
Why?
|
| Referral and Consultation | 1 | 2011 | 86 | 0.100 |
Why?
|
| Hematologic Tests | 1 | 2010 | 6 | 0.100 |
Why?
|
| Protein Array Analysis | 1 | 2010 | 10 | 0.100 |
Why?
|
| Leadership | 1 | 2011 | 96 | 0.090 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2010 | 10 | 0.090 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2010 | 21 | 0.090 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2010 | 16 | 0.090 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2010 | 32 | 0.090 |
Why?
|
| Rhabdomyosarcoma | 1 | 2009 | 4 | 0.090 |
Why?
|
| Animals | 4 | 2010 | 4552 | 0.090 |
Why?
|
| Models, Statistical | 1 | 2010 | 132 | 0.090 |
Why?
|
| Pleura | 2 | 2007 | 9 | 0.090 |
Why?
|
| Fibrosis | 1 | 2009 | 39 | 0.090 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2009 | 24 | 0.090 |
Why?
|
| Antifungal Agents | 1 | 2009 | 36 | 0.090 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2010 | 104 | 0.090 |
Why?
|
| Cause of Death | 1 | 2009 | 65 | 0.090 |
Why?
|
| Poland Syndrome | 1 | 2009 | 1 | 0.090 |
Why?
|
| Thoracoplasty | 1 | 2009 | 1 | 0.090 |
Why?
|
| Carcinoma, Large Cell | 1 | 2009 | 15 | 0.090 |
Why?
|
| Smoking | 1 | 2010 | 194 | 0.090 |
Why?
|
| Esophageal Fistula | 1 | 2008 | 1 | 0.080 |
Why?
|
| Silicone Elastomers | 1 | 2008 | 1 | 0.080 |
Why?
|
| Bronchial Fistula | 1 | 2008 | 2 | 0.080 |
Why?
|
| Esophageal Perforation | 1 | 2008 | 7 | 0.080 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2008 | 9 | 0.080 |
Why?
|
| Biomarkers | 3 | 2017 | 689 | 0.080 |
Why?
|
| Prosthesis Implantation | 1 | 2008 | 33 | 0.080 |
Why?
|
| Age Factors | 4 | 2014 | 843 | 0.080 |
Why?
|
| Intraoperative Care | 1 | 2008 | 44 | 0.080 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2008 | 39 | 0.080 |
Why?
|
| Esophageal Achalasia | 1 | 2007 | 19 | 0.080 |
Why?
|
| Incidence | 3 | 2021 | 756 | 0.080 |
Why?
|
| Botulinum Toxins, Type A | 1 | 2007 | 34 | 0.080 |
Why?
|
| Drainage | 1 | 2007 | 50 | 0.080 |
Why?
|
| Immunohistochemistry | 1 | 2008 | 391 | 0.080 |
Why?
|
| Healthcare Disparities | 1 | 2008 | 75 | 0.080 |
Why?
|
| Atrial Fibrillation | 1 | 2010 | 180 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 2 | 2017 | 68 | 0.070 |
Why?
|
| Delivery of Health Care | 1 | 2008 | 152 | 0.070 |
Why?
|
| Sepsis | 1 | 2008 | 144 | 0.070 |
Why?
|
| Prospective Studies | 5 | 2021 | 1811 | 0.070 |
Why?
|
| Radiotherapy Dosage | 3 | 2015 | 113 | 0.070 |
Why?
|
| Palliative Care | 1 | 2007 | 145 | 0.070 |
Why?
|
| Muscle, Skeletal | 1 | 2009 | 349 | 0.070 |
Why?
|
| Vinblastine | 1 | 2004 | 8 | 0.060 |
Why?
|
| Carboplatin | 3 | 2011 | 49 | 0.060 |
Why?
|
| Deoxycytidine | 1 | 2004 | 31 | 0.060 |
Why?
|
| Paclitaxel | 3 | 2011 | 74 | 0.060 |
Why?
|
| Radiography | 2 | 2013 | 678 | 0.060 |
Why?
|
| Societies, Medical | 2 | 2019 | 190 | 0.060 |
Why?
|
| Cell Line, Tumor | 2 | 2018 | 264 | 0.060 |
Why?
|
| Reoperation | 1 | 2008 | 932 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2009 | 1221 | 0.060 |
Why?
|
| Patient Care Planning | 1 | 2003 | 56 | 0.060 |
Why?
|
| ROC Curve | 2 | 2014 | 138 | 0.060 |
Why?
|
| Illinois | 2 | 2014 | 241 | 0.060 |
Why?
|
| Heart Transplantation | 2 | 1993 | 38 | 0.050 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2022 | 6 | 0.050 |
Why?
|
| Graft Rejection | 2 | 1993 | 76 | 0.050 |
Why?
|
| Pregnancy | 1 | 2003 | 403 | 0.050 |
Why?
|
| Lung Diseases | 2 | 1999 | 46 | 0.050 |
Why?
|
| Radiography, Thoracic | 2 | 2012 | 28 | 0.050 |
Why?
|
| Patient Discharge | 1 | 2022 | 149 | 0.050 |
Why?
|
| Chicago | 2 | 2016 | 865 | 0.050 |
Why?
|
| Etoposide | 2 | 2011 | 48 | 0.050 |
Why?
|
| Health Services Accessibility | 2 | 2014 | 101 | 0.050 |
Why?
|
| Mass Screening | 1 | 2022 | 177 | 0.050 |
Why?
|
| Tomography, Emission-Computed | 1 | 1999 | 11 | 0.050 |
Why?
|
| Aging | 1 | 2010 | 1593 | 0.050 |
Why?
|
| Electrocardiography | 3 | 2003 | 209 | 0.040 |
Why?
|
| Sarcoma, Small Cell | 1 | 1999 | 1 | 0.040 |
Why?
|
| Anesthesia, Epidural | 1 | 1999 | 25 | 0.040 |
Why?
|
| Sarcoma, Ewing | 1 | 1999 | 5 | 0.040 |
Why?
|
| Plasmacytoma | 1 | 1999 | 18 | 0.040 |
Why?
|
| Bupivacaine | 1 | 1999 | 54 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2000 | 394 | 0.040 |
Why?
|
| Radiation Injuries | 1 | 1999 | 34 | 0.040 |
Why?
|
| Anesthetics, Local | 1 | 1999 | 91 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2010 | 638 | 0.040 |
Why?
|
| Postoperative Care | 1 | 1999 | 127 | 0.040 |
Why?
|
| Endoscopy | 2 | 1997 | 181 | 0.040 |
Why?
|
| Remission Induction | 2 | 2010 | 96 | 0.040 |
Why?
|
| Dilatation | 1 | 2017 | 9 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2016 | 36 | 0.040 |
Why?
|
| History, 19th Century | 1 | 2016 | 66 | 0.040 |
Why?
|
| Diffusion of Innovation | 1 | 2016 | 38 | 0.040 |
Why?
|
| Pneumonia, Bacterial | 1 | 2016 | 9 | 0.040 |
Why?
|
| Tracheostomy | 1 | 2016 | 19 | 0.040 |
Why?
|
| Education, Medical, Graduate | 1 | 2016 | 79 | 0.030 |
Why?
|
| Pain, Postoperative | 1 | 1999 | 314 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2015 | 8 | 0.030 |
Why?
|
| Intubation, Intratracheal | 1 | 2016 | 77 | 0.030 |
Why?
|
| Minnesota | 1 | 2014 | 8 | 0.030 |
Why?
|
| Arrhythmias, Cardiac | 1 | 1996 | 149 | 0.030 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 138 | 0.030 |
Why?
|
| Actuarial Analysis | 1 | 2014 | 14 | 0.030 |
Why?
|
| Induction Chemotherapy | 1 | 2014 | 14 | 0.030 |
Why?
|
| Academies and Institutes | 1 | 2014 | 10 | 0.030 |
Why?
|
| Cancer Care Facilities | 1 | 2014 | 6 | 0.030 |
Why?
|
| Propensity Score | 1 | 2014 | 34 | 0.030 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2014 | 33 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2015 | 123 | 0.030 |
Why?
|
| Chemokine CCL3 | 1 | 2013 | 12 | 0.030 |
Why?
|
| Granuloma | 1 | 2013 | 13 | 0.030 |
Why?
|
| Coronary Circulation | 1 | 1993 | 43 | 0.030 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2013 | 14 | 0.030 |
Why?
|
| Chemokine CXCL12 | 1 | 2013 | 7 | 0.030 |
Why?
|
| Respiratory Tract Infections | 1 | 2013 | 22 | 0.030 |
Why?
|
| Internship and Residency | 1 | 2016 | 211 | 0.030 |
Why?
|
| Logistic Models | 1 | 2014 | 407 | 0.030 |
Why?
|
| Interleukin-10 | 1 | 2013 | 36 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2013 | 108 | 0.030 |
Why?
|
| Telemetry | 1 | 1992 | 11 | 0.030 |
Why?
|
| Prevalence | 1 | 2014 | 487 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2012 | 74 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 2012 | 52 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 788 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2013 | 215 | 0.030 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2011 | 20 | 0.030 |
Why?
|
| Medical Oncology | 1 | 2011 | 32 | 0.030 |
Why?
|
| Choice Behavior | 1 | 2011 | 56 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2010 | 9 | 0.020 |
Why?
|
| Serum | 1 | 2010 | 9 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2010 | 26 | 0.020 |
Why?
|
| Antibodies, Neoplasm | 1 | 2010 | 10 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 2010 | 37 | 0.020 |
Why?
|
| DNA Modification Methylases | 1 | 2010 | 3 | 0.020 |
Why?
|
| Death-Associated Protein Kinases | 1 | 2010 | 4 | 0.020 |
Why?
|
| DNA Repair Enzymes | 1 | 2010 | 6 | 0.020 |
Why?
|
| Monomeric GTP-Binding Proteins | 1 | 2010 | 6 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2010 | 29 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 40 | 0.020 |
Why?
|
| CpG Islands | 1 | 2010 | 34 | 0.020 |
Why?
|
| Cadherins | 1 | 2010 | 31 | 0.020 |
Why?
|
| Medical Records | 1 | 2010 | 29 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2010 | 50 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2010 | 80 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2010 | 99 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2010 | 75 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2009 | 75 | 0.020 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2009 | 35 | 0.020 |
Why?
|
| Proteomics | 1 | 2010 | 91 | 0.020 |
Why?
|
| Kidney Neoplasms | 1 | 2009 | 60 | 0.020 |
Why?
|
| Cisplatin | 1 | 2009 | 91 | 0.020 |
Why?
|
| Surgical Flaps | 1 | 2009 | 49 | 0.020 |
Why?
|
| Sutures | 1 | 2008 | 41 | 0.020 |
Why?
|
| Esophageal Diseases | 1 | 2007 | 4 | 0.020 |
Why?
|
| Ulcer | 1 | 2007 | 7 | 0.020 |
Why?
|
| Video Recording | 2 | 1997 | 47 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2004 | 16 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2004 | 138 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2004 | 223 | 0.020 |
Why?
|
| Respiratory Function Tests | 1 | 2003 | 32 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2004 | 437 | 0.010 |
Why?
|
| Weight Loss | 1 | 2003 | 99 | 0.010 |
Why?
|
| Transplantation, Heterotopic | 2 | 1993 | 12 | 0.010 |
Why?
|
| Dogs | 2 | 1993 | 253 | 0.010 |
Why?
|
| Health Status | 1 | 2003 | 227 | 0.010 |
Why?
|
| Pruritus | 1 | 1999 | 7 | 0.010 |
Why?
|
| Vital Capacity | 1 | 1999 | 9 | 0.010 |
Why?
|
| Fentanyl | 1 | 1999 | 21 | 0.010 |
Why?
|
| Urinary Retention | 1 | 1999 | 12 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2003 | 402 | 0.010 |
Why?
|
| Narcotics | 1 | 1999 | 34 | 0.010 |
Why?
|
| Thoracic Neoplasms | 1 | 1997 | 9 | 0.010 |
Why?
|
| Abdominal Neoplasms | 1 | 1997 | 9 | 0.010 |
Why?
|
| Pain Measurement | 1 | 1999 | 462 | 0.010 |
Why?
|
| Pericardial Window Techniques | 1 | 1996 | 3 | 0.010 |
Why?
|
| Treatment Failure | 1 | 1997 | 159 | 0.010 |
Why?
|
| Morbidity | 1 | 1996 | 63 | 0.010 |
Why?
|
| Radiotherapy | 1 | 1995 | 50 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 1995 | 101 | 0.010 |
Why?
|
| Recurrence | 1 | 1995 | 350 | 0.010 |
Why?
|
| Cyclosporine | 1 | 1993 | 15 | 0.010 |
Why?
|
| Electrodes, Implanted | 1 | 1992 | 46 | 0.010 |
Why?
|
| Monitoring, Physiologic | 1 | 1992 | 92 | 0.010 |
Why?
|
| Myocardium | 1 | 1992 | 139 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 1992 | 132 | 0.010 |
Why?
|